Africa Health 2024: Showcasing Innovation, Revolutionizing and Decentralizing Infectious Disease Testing

On October 22, 2024, Africa Health 2024 successfully opened at the Cape Town International Convention Center in South Africa. Pluslife showcased multiple innovative products at booth H1.C26, highlighting its molecular POCT product for tuberculosis, which supports dual-sample detection via tongue swab and sputum, as well as its molecular POCT product for Human Papillomavirus (HPV), along with additional respiratory and animal health products.

Africa Health 2024 brought together over 500 exhibitors from more than 50 countries worldwide. Pluslife’s molecular POCT product for tuberculosis quickly became a focal point of the event due to its innovation and practical application. During the exhibition, our team engaged in in-depth discussions with exhibitors from various regions, exchanging industry insights, deepening friendships with long-term partners, and establishing initial connections with new clients, creating more opportunities for future collaborations.

Pluslife’s molecular POCT product for tuberculosis—supports dual-sample detection using sputum and tongue swabs, providing high-performance, low-cost, rapid, and convenient pathogen detection for tuberculosis. This innovative product meets the demand for decentralized applications, making it especially suitable for resource-limited primary healthcare institutions. Its launch signifies a shift from “symptom-driven diagnosis” to “proactive screening,” significantly advancing tuberculosis prevention efforts and marking a key step toward the goal of ending the TB epidemic by 2035.

Currently, this product leads globally as the only mature, low-cost rapid molecular POCT solution for tuberculosis. It has received high recognition and support from renowned organizations, including the World Health Organization, the Foundation for Innovative New Diagnostics (FIND), and the Bill & Melinda Gates Foundation.